Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab
- 257 Downloads
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare cause of pulmonary hypertension that is associated with malignancies and is marked by the presence of non-occlusive tumor emboli and fibrocellular intimal proliferation of small pulmonary arteries leading to increased pulmonary vascular resistance and right heart failure. The diagnosis of PTTM is challenging to make pre-mortem and guidelines on treatment are lacking.
A 45-year-old woman with advanced squamous cell carcinoma of the cervix developed symptoms of dyspnea and evidence of right heart failure during a phase I clinical trial with cediranib and durvalumab. After an extensive evaluation, pre-capillary pulmonary hypertension was confirmed by right heart catheterization. Vasodilator therapy was initiated but resulted in the development of symptomatic hypoxemia and was discontinued. Despite continued supportive care, she continued to decline and was transitioned to hospice care. At autopsy, the cause of her right heart failure was found to be due to PTTM with features of pulmonary veno-occlusive disease (PVOD).
PTTM and PVOD are important diagnoses to consider in patients with a malignancy and the development of right heart failure and may be manifestations of a spectrum of similar disease processes.
KeywordsPulmonary tumor thrombotic microangiopathy Pulmonary hypertension Cediranib Durvalumab Cervical cancer
chronic thromboembolic pulmonary hypertension
hepatocyte growth factor
National Institutes of Health
pulmonary arterial hypertension
programmed death-ligand 1
pulmonary tumor thrombotic microangiopathy
pulmonary veno-occlusive disease
tricuspid annular plane systolic excursion
tumor necrosis factor alpha
vascular endothelial growth factor
vascular endothelial growth factor receptor
- VQ scan
ventilation perfusion scan
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare condition characterized by microscopic tumor cell emboli, which cause proliferative changes in the pulmonary microvasculature leading to a syndrome of hypoxemia, pulmonary hypertension, right heart failure and death . In the initial report, unique pathologic changes in 21 patients were described with non-occluding microscopic tumor emboli limited to the small pulmonary arterial vessel wall, isolated or clumped in the vessel lumen and often with secondary thrombosis. The endothelial attachment of tumor cells was associated with fibrocellular intimal proliferation. The resultant obstruction of the small arteries and increase in pulmonary vascular resistance is thought to contribute to the clinical presentation of progressive cor pulmonale and death. It was notable that in nearly all the described cases lymphangiosis carcinomatosa was present, but the relationship to PTTM was unclear. Thus, PTTM is thought to be a unique clinical entity based on the presence of intimal proliferation, distinguishing it from obstructive pulmonary tumor emboli. In a larger case series, adenocarcinoma was the most common underlying malignancy and in nearly all cases the tumor emboli were positive for vascular endothelial growth factor (VEGF), platelet derived growth factor and tissue factor by immunohistochemistry . Over-expression of these growth factors on the surface of the embolized tumor cell may result in a trophic effect on the pulmonary vascular endothelium, leading to the described pathologic findings . Here we describe a woman being treated with the combination of a VEGF receptor (VEGFR) inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor who developed pulmonary hypertension and right heart failure and was subsequently found to have PTTM with features of pulmonary veno-occlusive disease (PVOD).
A 45-year-old woman with metastatic squamous cell carcinoma of the cervix refractory to standard of care chemotherapy was referred to the National Institutes of Health (NIH) for enrollment in a Phase I clinical trial (NCT02484404) of combination therapy with daily cediranib, a VEGFR tyrosine kinase inhibitor, and once every 2 weeks of durvalumab, a PD-L1 inhibitor. Her first four treatment cycles were well tolerated. Treatment related side effects included hypertension, subclinical hypothyroidism, non-nephrotic range proteinuria and mild diarrhea.
Hemodynamic measures from left and right heart catheterization with vasodilator testing
Nitric Oxide (40 ppm) plus 100% O2
Heart rate, beats per minute
Mean right atrial pressure, mmHg
Pulmonary artery pressure (mean), mmHg
Mean pulmonary artery occlusion pressure, mmHg
Aortic pressure (mean), mmHg
Left ventricle end-diastolic pressure, mmHg
Arterial blood gas, pH/pCO2/pO2
Arterial oxygen saturation, %
Mixed venous oxygen saturation, %
Cardiac indexa, L/min/m2
Pulmonary vascular resistance, Wood units
We present a case of a woman with metastatic squamous cell carcinoma of the cervix who developed pulmonary hypertension and right heart failure during combination treatment with a VEGFR inhibitor and a PD-L1 inhibitor. At autopsy, she was found to have PTTM with features of PVOD.
A definitive pre-mortem diagnosis of PTTM is challenging as a number of other causes of right heart failure have a similar clinical presentation . For example, our patient’s initial CT angiogram revealed prominent bibasilar septal lines, which may have represented lymphangitic spread of tumor, drug-induced pulmonary toxicity or PVOD . Other non-specific radiographic findings in PTTM include multifocal beaded peripheral pulmonary arteries, diffuse thickening of the intralobular septa or peripheral wedge-shaped opacities suggestive of infarction . A VQ scan can reveal peripheral unmatched perfusion defects in patients with tumor emboli . However, this finding is also present in patients with acute pulmonary emboli or CTEPH and cannot be easily distinguished . Pulmonary microvascular cytology has been used as a diagnostic tool to identify circulating tumor cells, however these cells can be mistaken as normal pulmonary megakaryocytes . The presence of right ventricular hypertrophy by cardiac MRI suggested subacute or chronic pulmonary vascular disease in our patient and right and left heart catheterization confirmed the presence of pre-capillary pulmonary hypertension. Therefore other conditions in the differential included drug-induced pulmonary arterial hypertension (PAH) and CTEPH.
The development of hypoxia after the start of prostacyclin treatment raised suspicion for PVOD as the underlying cause of her pulmonary hypertension. Although histopathologically PVOD typically affects post-capillary venules, hemodynamically PVOD has a pre-capillary pattern on right heart catheterization similar to our patient . In addition, the patient’s regimen included multiple chemotherapeutic agents including cisplatin and docetaxel and radiation therapy, all of which are associated with development of PVOD [12, 13]. However, based on the original descriptions of PTTM, concurrent histological evidence of PVOD in our patient was unexpected . Nevertheless, cases of PTTM with pulmonary venous involvement have been previously reported [4, 14].
Many cases of PTTM are treated in a similar manner to idiopathic PAH, although it is unclear such therapies are effective and as demonstrated by this case, they may be harmful. In patients with PVOD, pulmonary edema may develop with pulmonary vasodilator therapy due to increased pulmonary artery blood flow in the face of high post-capillary venule resistance. Alternatively, systemic administration of a potent pulmonary vasodilator may cause ventilation and perfusion mismatching leading to hypoxia. Based on the pulmonary histopathology, the hypoxemia seen in our patient was likely due to both pulmonary edema from venule obstruction and ventilation perfusion mismatch.
In contrast to a suspected role for angiogenic growth factors such as VEGF in the pathogenesis of PTTM, and anecdotal case reports of positive outcomes with imatinib treatment  our patient not only developed, but also progressed to symptomatic PTTM during prolonged treatment with a VEGFR inhibitor. Importantly, pharmacokinetic studies done in our patient revealed that co-administration of durvalumab significantly decreased clearance of cediranib . While the effect of VEGFR inhibition on the development or progression of PTTM is unknown, there is experimental evidence that exposure to a single dose of a VEGFR inhibitor, semaxanib (SU-5416), followed by chronic hypoxia leads to angioobliterative PAH in rats that mimics the histopathologic findings in patients with PAH, including hyperproliferative plexiform lesions . In rodents, VEGFR blockade induces widespread pulmonary artery endothelial cell apoptosis which in the presence of chronic hypoxia is thought to result in the development of an apoptosis-resistant, hyperproliferative endothelial cell phenotype . As a result of VEGFR blockade in this model, elevated levels of VEGFR ligands as well as other angiogenic factors (e.g. fibroblast growth factor and placental growth factor) may promote hyperproliferation and vascular remodeling . In patients treated with VEGFR inhibitors, elevated circulating levels of fibroblast growth factor, placental growth factor and hepatocyte growth factor (HGF) have also been detected prior to disease progression [19, 20]. Similarly, in murine models of human non-small cell lung cancer, treatment with vandetanib and cediranib initially led to tumor regression followed by resistance to therapy and progression that was associated with upregulation of both HGF and its receptor, c-MET . Studies of the tumor microvasculature in these murine models revealed HGF-dependent dysregulated angiogenesis with tortuous blood vessel formation. Interestingly, at autopsy immunohistochemical staining revealed lung metastatic foci that were VEGF negative but HGF positive. Thus, it is tempting to speculate that prolonged exposure to high levels of the VEGF receptor inhibitor could similarly provoke an abnormal response in the pulmonary vasculature that either induced or accelerated the development of PTTM in our patient. Moreover, levels of interferon and TNFα as well as other inflammatory cytokines closely linked to pulmonary vascular remodeling in PAH [22, 23, 24] may be elevated in the setting of PD-L1 blockade due to compensatory feedback mechanisms [25, 26]. Therefore, although PD1 and PD-L1 inhibitors have not been associated with the development of pulmonary hypertension , this ensuing pro-inflammatory state may act synergistically with VEGFR inhibition to disrupt angiogenesis and promote abnormal vessel formation . In our patient, PD-L1 staining was performed on a lymph node taken prior to checkpoint inhibitor therapy and revealed positive staining on approximately 20% of tumor cells. Nevertheless, any association of VEGFR and PD-L1 inhibition to the development of PTTM and PVOD remains speculative.
Histopathology is necessary to definitively diagnose PTTM, yet a surgical lung biopsy is prohibitively risky in the presence of severe pulmonary hypertension and right heart failure. Thus, similar to our report, mechanistic studies of PTTM are lacking due to the difficulty in making a definitive pre-mortem diagnosis. Finally, as a single case report, there are many inherent limitations to our manuscript. The major limitation is the inability to establish causality between the patient’s experimental therapy and her risk for the development of PTTM.
In the setting of malignancy, PTTM should be included in the differential diagnosis of a patient that presents with subacute to chronic pulmonary hypertension. Serial echocardiography may be useful for identifying evidence of pulmonary hypertension or right ventricular dysfunction prior to the onset of severe symptoms. However, these findings are non-specific and there are no established criteria for screening patients who are at higher risk for developing PTTM. This case report illustrates that a pre-mortem diagnosis of PTTM is difficult to confirm, treatment guidelines are lacking and the prognosis is poor. In addition, our case provides further support for the premise that both PTTM and PVOD share a common pathogenesis and may be manifestations of a spectrum of similar disease processes.
The authors would like to thank Kelly Byrne for her assistance in preparation of the manuscript.
This work was supported in part by the Intramural Research Program of the National Institutes of Health Clinical Center.
DAS, JME and MAS participated in the drafting of the manuscript. JML, JME and MAS were involved in the management of the case. DP and DEK interpreted the gross and histopathology. CJP performed the pharmacokinetic studies. All authors read and approved the final version of this manuscript.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institutes of Health.
Ethics approval and consent to participate
Consent for publication
Written informed consent was obtained from the patient’s next of kin to report details of this patient’s clinical course and to publish associated clinical images.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 16.Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, et al. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1–3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. J Clin Oncol. 2017;35(19):2193–202.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 2001;195(3):367–74.CrossRefPubMedGoogle Scholar
- 19.Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(3):453–9.CrossRefPubMedGoogle Scholar
- 23.Hurst LA, Dunmore BJ, Long L, Crosby A, Al-Lamki R, Deighton J, Southwood M, Yang X, Nikolic MZ, Herrera B, et al. TNFalpha drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nat Commun. 2017;8:14079.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, Shinya E, Takahashi H, Tamada K, Chen L, et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood. 2010;116(7):1124–31.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, Herskovitz J, Elsaesser H, Snell LM, Wilson EB, et al. Type I and type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence. PLoS Pathog. 2016;12(1):e1005356.CrossRefPubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.